Year: 2020
Type: article
Abstract: The misfolding and aberrant aggregation of proteins into fibrillar structures is a key factor in some of the most prevalent human diseases, including diabetes and dementia. Low molecular weight oligomers are thought to be a central factor in the pathology of these diseases, as well as critical intermediates in the fibril formation process, and as such have received much recent attention. Moreover, on-pathway oligomeric intermediates are potential targets for therapeutic strategies aimed at interrupting the fibril formation process. However, a consistent framework for distinguishing on-pathway from off-pathway oligomers has hitherto been lacking and, in particular, no consensus definition of on- and off-pathway oligomers is available. In this paper, we argue that a non-binary definition of oligomers' contribution to fibril-forming pathways may be more informative and we suggest a quantitative framework, in which each oligomeric species is assigned a value between 0 and 1 describing its relative contribution to the formation of fibrils. First, we clarify the distinction between oligomers and fibrils, and then we use the formalism of reaction networks to develop a general definition for on-pathway oligomers, that yields meaningful classifications in the context of amyloid formation. By applying these concepts to Monte Carlo simulations of a minimal aggregating system, and by revisiting several previous studies of amyloid oligomers in light of our new framework, we demonstrate how to perform these classifications in practice. For each oligomeric species we obtain the degree to which it is on-pathway, highlighting the most effective pharmaceutical targets for the inhibition of amyloid fibril formation.
Source: Chemical Science
DOI: 10.1039/c9sc06501f
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: National Science Foundation, Frances and Augustus Newman Foundation, Wellcome Trust, Schiff Foundation, Royal Society, Academy of Medical Sciences, European Commission, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Lundbeckfonden, Vetenskapsrådet, Novo Nordisk Fonden, H. Lundbeck A/S, Biotechnology and Biological Sciences Research Council, Sidney Sussex College, University of Cambridge, FP7 Ideas: European Research Council
Awards: G1054401548, Molecular mechanism of amyloid β aggregation, G119964413, G1323383031, G1550271704, G2109279595, G2581043028, G3207356259, G393177772, G4104599821, Determining Physical Properties of Heterogeneous Protein Complexes in Small Volumes, G5702163051, G6001733700, G7108483317, G7474645479, New Approaches for Microscopic Analysis of Macromolecular Assemblies
OpenAlex ID: W3033124231
